<?xml version="1.0" encoding="UTF-8"?><OAI-PMH
	xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd"><responseDate>2019-03-02T19:49:33Z</responseDate><request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:3732535" metadataPrefix="pmc">https:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi</request><GetRecord><record><header><identifier>oai:pubmedcentral.nih.gov:3732535</identifier><datestamp>2014-02-01</datestamp><setSpec>nihpa</setSpec><setSpec>pmc-open</setSpec><setSpec>manuscript</setSpec></header><metadata><article xmlns="https://jats.nlm.nih.gov/ns/archiving/1.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.0/ https://jats.nlm.nih.gov/archiving/1.0/xsd/JATS-archivearticle1.xsd" article-type="research-article">
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-journal-id">0410462</journal-id>
      <journal-id journal-id-type="pubmed-jr-id">6011</journal-id>
      <journal-id journal-id-type="nlm-ta">Nature</journal-id>
      <journal-id journal-id-type="iso-abbrev">Nature</journal-id>
      <journal-title-group>
        <journal-title>Nature</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">0028-0836</issn>
      <issn pub-type="epub">1476-4687</issn>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="accession">PMC3732535</article-id>
      <article-id pub-id-type="pmcid">PMC3732535</article-id>
      <article-id pub-id-type="pmc-uid">3732535</article-id>
      <article-id pub-id-type="pmid">23812588</article-id>
      <article-id pub-id-type="pmid">23812588</article-id>
      <article-id pub-id-type="doi">10.1038/nature12287</article-id>
      <article-id pub-id-type="manuscript">nihpa479702</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Article</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>A stable transcription factor complex nucleated by oligomeric AML1-ETO controls leukaemogenesis</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Sun</surname>
            <given-names>Xiao-Jian</given-names>
          </name>
          <xref ref-type="aff" rid="A1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Wang</surname>
            <given-names>Zhanxin</given-names>
          </name>
          <xref ref-type="aff" rid="A2">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Wang</surname>
            <given-names>Lan</given-names>
          </name>
          <xref ref-type="aff" rid="A3">3</xref>
          <xref ref-type="aff" rid="A4">4</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Jiang</surname>
            <given-names>Yanwen</given-names>
          </name>
          <xref ref-type="aff" rid="A5">5</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Kost</surname>
            <given-names>Nils</given-names>
          </name>
          <xref ref-type="aff" rid="A6">6</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Soong</surname>
            <given-names>T. David</given-names>
          </name>
          <xref ref-type="aff" rid="A7">7</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Chen</surname>
            <given-names>Wei-Yi</given-names>
          </name>
          <xref ref-type="aff" rid="A1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Tang</surname>
            <given-names>Zhanyun</given-names>
          </name>
          <xref ref-type="aff" rid="A1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Nakadai</surname>
            <given-names>Tomoyoshi</given-names>
          </name>
          <xref ref-type="aff" rid="A1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Elemento</surname>
            <given-names>Olivier</given-names>
          </name>
          <xref ref-type="aff" rid="A7">7</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Fischle</surname>
            <given-names>Wolfgang</given-names>
          </name>
          <xref ref-type="aff" rid="A6">6</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Melnick</surname>
            <given-names>Ari</given-names>
          </name>
          <xref ref-type="aff" rid="A5">5</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Patel</surname>
            <given-names>Dinshaw J.</given-names>
          </name>
          <xref ref-type="aff" rid="A2">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Nimer</surname>
            <given-names>Stephen D.</given-names>
          </name>
          <xref ref-type="aff" rid="A3">3</xref>
          <xref ref-type="aff" rid="A4">4</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Roeder</surname>
            <given-names>Robert G.</given-names>
          </name>
          <xref ref-type="aff" rid="A1">1</xref>
        </contrib>
      </contrib-group>
      <aff id="A1"><label>1</label>Laboratory of Biochemistry and Molecular Biology, The Rockefeller University, New York, New York 10065, USA</aff>
      <aff id="A2"><label>2</label>Structural Biology Program, Sloan-Kettering Institute, Memorial Sloan-Kettering Cancer Center, New York, New York 10065, USA</aff>
      <aff id="A3"><label>3</label>Molecular Pharmacology and Chemistry Program, Sloan-Kettering Institute, Memorial Sloan-Kettering Cancer Center, New York, New York 10065, USA</aff>
      <aff id="A4"><label>4</label>Sylvester Comprehensive Cancer Center, Miller School of Medicine, University of Miami, Miami, FL 33136, USA</aff>
      <aff id="A5"><label>5</label>Division of Hematology and Medical Oncology, Department of Medicine, Weill Cornell Medical College, New York, New York 10065, USA</aff>
      <aff id="A6"><label>6</label>Laboratory of Chromatin Biochemistry, Max Planck Institute for Biophysical Chemistry, 37077 Gottingen, Germany</aff>
      <aff id="A7"><label>7</label>Institute for Computational Biomedicine, Weill Cornell Medical College, New York, New York 10065, USA</aff>
      <author-notes>
        <corresp id="FN1">Correspondence and requests for materials should be addressed to R.G.R. (<email>roeder@rockefeller.edu</email>)</corresp>
      </author-notes>
      <pub-date pub-type="nihms-submitted">
        <day>10</day>
        <month>6</month>
        <year>2013</year>
      </pub-date>
      <pub-date pub-type="epub">
        <day>30</day>
        <month>6</month>
        <year>2013</year>
      </pub-date>
      <pub-date pub-type="ppub">
        <day>1</day>
        <month>8</month>
        <year>2013</year>
      </pub-date>
      <pub-date pub-type="pmc-release">
        <day>01</day>
        <month>2</month>
        <year>2014</year>
      </pub-date>
      <volume>500</volume>
      <issue>7460</issue>
      <fpage>93</fpage>
      <lpage>97</lpage>
      <!--elocation-id from pubmed: 10.1038/nature12287-->
      <permissions>
        <license>
          <license-p>Users may view, print, copy, download and text and data- mine the content in such documents, for the purposes of academic research, subject always to the full Conditions of use: 
<uri xlink:type="simple" xlink:href="http://www.nature.com/authors/editorial_policies/license.html#terms">http://www.nature.com/authors/editorial_policies/license.html#terms</uri></license-p>
        </license>
      </permissions>
      <abstract>
        <p id="P1">Transcription factors are frequently altered in leukaemia through chromosomal translocation, mutation or aberrant expression<sup><xref rid="R1" ref-type="bibr">1</xref></sup>. AML1-ETO, a fusion protein generated by the t(8;21) translocation in acute myeloid leukaemia (AML), is a transcription factor implicated in both gene repression and activation<sup><xref rid="R2" ref-type="bibr">2</xref></sup>. AML1-ETO oligomerization, mediated by the NHR2 domain, is critical for leukaemogenesis<sup><xref rid="R3" ref-type="bibr">3</xref>â<xref rid="R6" ref-type="bibr">6</xref></sup>, making it important to identify coregulatory factors that âreadâ the NHR2 oligomerization and contribute to leukaemogenesis<sup><xref rid="R4" ref-type="bibr">4</xref></sup>. We now show that, in leukaemic cells, AML1-ETO resides in and functions through a stable protein complex (AETFC) that contains several haematopoietic transcription (co)factors. These AETFC components stabilize the complex through multivalent interactions, provide multiple DNA-binding domains for diverse target genes, colocalize genome-wide, cooperatively regulate gene expression, and contribute to leukaemogenesis. Within the AETFC complex, AML1-ETO oligomerization is required for a specific interaction between the oligomerized NHR2 domain and a novel NHR2-binding (N2B) motif in E proteins. Crystallographic analysis of the NHR2-N2B complex reveals a unique interaction pattern in which an N2B peptide makes direct contact with side chains of two NHR2 domains as a dimer, providing a novel model of how dimeric/oligomeric transcription factors create a new protein-binding interface through dimerization/oligomerization. Intriguingly, disruption of this interaction by point mutations abrogates AML1-ETOâinduced haematopoietic stem/progenitor cell self-renewal and leukaemogenesis. These results reveal new mechanisms of action of AML1-ETO and a potential therapeutic target in t(8;21)<sup>+</sup> AML.</p>
      </abstract>
    </article-meta>
  </front>
  <body>
    <p id="P2">AML1-ETO consists of the DNA-binding (RUNT) domain of the haematopoietic transcription factor AML1/RUNX1 and four conserved domains (NHR1-4) of ETO<sup>2</sup>. These domains differentially contribute to AML1-ETO activities in regulating cell proliferation, differentiation and survival<sup><xref rid="R2" ref-type="bibr">2</xref></sup>. In particular, the NHR2-mediated oligomerization of AML1-ETO has been shown to be critical for leukaemogenesis<sup><xref rid="R3" ref-type="bibr">3</xref>â<xref rid="R6" ref-type="bibr">6</xref></sup>. While oligomerization endows AML1-ETO with a DNA-binding preference for duplicated AML1 sites<sup><xref rid="R7" ref-type="bibr">7</xref></sup>, it is important to explore the possibility that oligomerization might also affect cofactor recruitment and function. AML1-ETO is generally thought to act as a transcriptional repressor by recruiting corepressors (e.g., NCoR and HDACs) to AML1 target genes<sup><xref rid="R8" ref-type="bibr">8</xref>â<xref rid="R10" ref-type="bibr">10</xref></sup> or by interacting and interfering with other transcription factors (e.g., ETS family proteins, C/EBPÎ±, GATA1 and E proteins) <sup><xref rid="R11" ref-type="bibr">11</xref>â<xref rid="R17" ref-type="bibr">17</xref></sup>. In relation to its functions in gene activation, AML1-ETO also can recruit coactivators p300<sup><xref rid="R18" ref-type="bibr">18</xref></sup> and PRMT1<sup><xref rid="R19" ref-type="bibr">19</xref></sup>. Beyond these indications of dynamic AML1-ETO interactions with diverse proteins, it has been unclear whether AML1-ETO resides in any stable multiprotein complex(es) that might endow it with new properties that lead to altered regulatory events and corresponding cellular functions.</p>
    <p id="P3">To identify a natural AML1-ETOâcontaining complex in leukaemic cells, we used patient-derived Kasumi-1 cells and an antigen-purified anti-ETO antibody that showed high specificity and affinity (<xref rid="SD1" ref-type="supplementary-material">Supplementary Fig. 2a, b</xref>). The absence of wild-type (WT) ETO in Kasumi-1 cells<sup><xref rid="R20" ref-type="bibr">20</xref></sup> allowed selective isolation of AML1-ETO from derived nuclear extracts, which contained most AML1-ETO (<xref rid="SD1" ref-type="supplementary-material">Supplementary Fig. 2c</xref>). Using a high stringency buffer to preclude weak or non-specific interactions, we isolated a stable <underline>A</underline>ML1-<underline>E</underline>TOâcontaining transcription factor complex (AETFC) whose components were identified by SDS-PAGE (<xref rid="F1" ref-type="fig">Fig. 1a</xref>) and mass spectrometry (<xref rid="SD1" ref-type="supplementary-material">Supplementary Fig. 3a</xref>) and confirmed by immunoblot (<xref rid="F1" ref-type="fig">Fig. 1b</xref>). These components include the AML1-binding partner CBFÎ², E proteins HEB and E2A, the haematopoietic E-box-binding transcription factor LYL1 (but not its homologue SCL/TAL1), the LIM domain protein LMO2 and its interacting partner LDB1. While interactions among some of these factors (or homologues) have been implicated in a related GATA1-SCL-E2A-LMO2-LDB1 complex in erythrocytes<sup><xref rid="R21" ref-type="bibr">21</xref></sup>, their connection with AML1-ETO in AML is unknown. A gel-filtration analysis indicated that they form a stable, high molecular weight complex (<xref rid="SD1" ref-type="supplementary-material">Supplementary Fig. 3b</xref>). We then employed baculovirus vectors to reconstitute AETFC and to characterize the pairwise interactions within AETFC (<xref rid="SD1" ref-type="supplementary-material">Supplementary Fig. 3c, d</xref>). The results revealed an interaction network (<xref rid="F1" ref-type="fig">Fig. 1c</xref>) in which several strong interactions link all the components one by one and likely play a major role in AETFC assembly, while some weak interactions may further stabilize the complex.</p>
    <p id="P4">To assess potentially joint functions of the AETFC components, we performed a ChIP-seq analysis of AML1-ETO, HEB, E2A and LMO2 in Kasumi-1 cells and validated some binding events by ChIP-qPCR â for example, on the well-established <italic>CSF1R FIRE</italic><sup><xref rid="R22" ref-type="bibr">22</xref></sup> and <italic>SPI1 URE</italic><sup><xref rid="R23" ref-type="bibr">23</xref></sup> enhancers. Comparison of their binding sites and enrichment scores indicated a genome-wide colocalization and a correlation of binding strengths, and suggested that the interactions among the components facilitate their binding to the genome (<xref rid="F1" ref-type="fig">Fig. 1d</xref> and <xref rid="SD1" ref-type="supplementary-material">Supplementary Fig. 4aâd</xref>). Sequence analysis of AML1-ETOâbinding regions revealed that both AML1 sites and E-boxes (recognized by E proteins and other bHLH transcription factors including LYL1) were over-represented (<xref rid="SD1" ref-type="supplementary-material">Supplementary Fig. 4e, f</xref>), suggesting that, in addition to direct binding to DNA through the RUNT domain, AML1-ETO also binds to DNA indirectly through its interaction with the E-box-binding AETFC components.</p>
    <p id="P5">To investigate the role of AETFC in regulating gene expression and leukaemogenesis, we performed gene knockdown in Kasumi-1 cells and in a mouse leukaemic model induced by AML1-ETO9a (AE9a), a leukaemogenic, truncated form of AML1-ETO<sup><xref rid="R24" ref-type="bibr">24</xref></sup>. First of all, individual knockdowns of AETFC components (but not SCL) significantly decreased some other components at the protein level but not at the mRNA level (<xref rid="SD1" ref-type="supplementary-material">Supplementary Fig. 5a, b</xref>), suggesting a mutual stabilization mechanism within AETFC. Interestingly, <italic>SCL</italic> mRNA was downregulated by knockdown of any AETFC component (<xref rid="SD1" ref-type="supplementary-material">Supplementary Fig. 5b</xref>). Since the 3â² haematopoietic enhancer of <italic>SCL</italic><sup><xref rid="R25" ref-type="bibr">25</xref></sup> is bound by AETFC (<xref rid="SD1" ref-type="supplementary-material">Supplementary Fig. 5c</xref>), <italic>SCL</italic> is likely a direct target gene of AETFC. In an extension of this observation, global ChIP-seq and RNA-seq analyses revealed that the genes up- and down-regulated by one AETFC component were similarly regulated by others (<xref rid="F1" ref-type="fig">Fig. 1e</xref> and <xref rid="SD1" ref-type="supplementary-material">Supplementary Fig. 5d</xref>). These analyses led to the identification of a set of genes that are both directly bound and cooperatively regulated by AETFC components (<xref rid="SD1" ref-type="supplementary-material">Supplementary Fig. 5e</xref> and <xref rid="SD1" ref-type="supplementary-material">Supplementary Tables 1, 2</xref>). We next showed that knockdowns of AETFC components considerably delayed leukaemogenesis in mice (<xref rid="F1" ref-type="fig">Fig. 1f</xref> and <xref rid="SD1" ref-type="supplementary-material">Supplementary Fig. 6</xref>), indicating a requirement for AETFC components in AML1-ETOâmediated leukaemogenesis. Notably, double-knockdown of HEB and E2A most dramatically delayed leukaemogenesis, which is consistent with the primary importance of these two E proteins in AETFC assembly/stabilization (<xref rid="F1" ref-type="fig">Fig. 1c</xref> and <xref rid="SD1" ref-type="supplementary-material">Supplementary Fig. 5a</xref>).</p>
    <p id="P6">To further investigate the function and mechanism of these two E proteins in AETFC, we performed co-immunoprecipitation (co-IP) experiments with a series of deletion mutants of AML1-ETO and HEB, as well as a GST pull-down assay with isolated domains. These analyses clearly established multivalent interactions between AML1-ETO and E proteins and, interestingly, showed that the functionally critical NHR2 domain mediates not only oligomerization but also an interaction with E proteins (<xref rid="SD1" ref-type="supplementary-material">Supplementary Fig. 7</xref>). We next took several steps to clarify the relationship between NHR2-oligomerization and the NHR2-E protein interaction. First, we found that the multisite NHR2 mutation m7, which disrupts NHR2-oligomerization<sup><xref rid="R4" ref-type="bibr">4</xref></sup>, also completely disrupts the NHR2-E protein interaction (<xref rid="F2" ref-type="fig">Fig. 2a, b</xref>). Second, we performed an exhaustive screening of NHR2 mutations and found that NHR2-oligomerization and the NHR2-E protein interaction involve different surfaces of the NHR2 Î±-helix (<xref rid="F2" ref-type="fig">Fig. 2aâd</xref>). Accordingly, we identified point mutations that specifically disrupt the NHR2-E protein interaction (<xref rid="F2" ref-type="fig">Fig. 2b</xref>) but not NHR2-oligomerization, as indicated by co-IP (<xref rid="SD1" ref-type="supplementary-material">Supplementary Fig. 8</xref>) and gel-filtration (<xref rid="F2" ref-type="fig">Fig. 2c</xref>) assays. Third, we found that the mutant-WT AML1-ETO heterodimer, unlike the WT homodimer, failed to bind HEB-ÎAD1 (<xref rid="F2" ref-type="fig">Fig. 2e</xref>), indicating that a single WT AML1-ETO in the dimer is unable to bind HEB-ÎAD1 and, thus, that NHR2-oligomerization is required for the NHR2-E protein interaction.</p>
    <p id="P7">To further clarify the mechanism of how E proteins recognize the NHR2 oligomer, we first mapped the NHR2-binding (N2B) region in HEB. As a result, we identified a novel, 18-amino acid N2B motif that is required for the NHR2-interaction (<xref rid="F3" ref-type="fig">Fig. 3a, b</xref>, and <xref rid="SD1" ref-type="supplementary-material">Supplementary Fig. 9</xref>). A subsequent X-ray crystallographic analysis of the NHR2-N2B complex showed that NHR2 formed a tetrameric Î±-helical bundle<sup><xref rid="R4" ref-type="bibr">4</xref></sup> with four N2B peptides bound on two symmetrically-related surfaces with 1:1 stoichiometry (<xref rid="F3" ref-type="fig">Fig. 3c</xref> and <xref rid="SD1" ref-type="supplementary-material">Supplementary Fig. 10a</xref>). After an independent validation of directionality and register of the bound N2B peptide (<xref rid="SD1" ref-type="supplementary-material">Supplementary Fig. 10b, c</xref>), we demonstrated that a given N2B binds to a narrow surface channel created by two NHR2 helices, with P191 and S192 of N2B inserted deeply into a surface pocket (<xref rid="F3" ref-type="fig">Fig. 3d</xref>). Notably, P191 of N2B interacts through hydrogen bonding with S522 from one NHR2 helix, while S192 and V194 form hydrogen bonds with E501 and H504, respectively, from another NHR2 helix (<xref rid="F3" ref-type="fig">Fig. 3e</xref>). This unique interaction pattern confirms the results of the cell-based assay (<xref rid="F2" ref-type="fig">Fig. 2e</xref>) by showing, unequivocally, that two dimerized NHR2 helices are required for the N2B-interaction. To further verify the binding specificity, we made mutations in NHR2 and in a shorter N2B(182-196) peptide and determined their interactions using fluorescence polarization (FP) assays. The results showed that the binding of such a short N2B peptide to NHR2 is relatively weak but highly specific since the mutation in NHR2 (mNHR2; <xref rid="SD1" ref-type="supplementary-material">Supplementary Fig. 11a</xref>) completely abolished the binding (<xref rid="F3" ref-type="fig">Fig. 3f</xref>). Reciprocally, single mutations of the key residues P187, P191 or S192 of N2B also significantly reduced the binding, whereas mutation of the less important P188 had very little effect (<xref rid="F3" ref-type="fig">Fig. 3g</xref>).</p>
    <p id="P8">To study the biological relevance of the AML1-ETOâE protein interactions in leukaemogenesis, we introduced the mNHR2 mutation that specifically disrupts the NHR2-N2B interaction without affecting NHR2-oligomerization (<xref rid="F2" ref-type="fig">Figs. 2c</xref>, <xref rid="F3" ref-type="fig">3f</xref> and <xref rid="SD1" ref-type="supplementary-material">Supplementary Fig. 11a, b</xref>), as well as the mNHR1 mutation that blocks the NHR1-AD1 interaction<sup><xref rid="R26" ref-type="bibr">26</xref></sup>. We first employed the human CD34<sup>+</sup> haematopoietic stem/progenitor cell (HSPC) self-renewal assay<sup><xref rid="R27" ref-type="bibr">27</xref></sup>. While AML1-ETO and mutants exhibited comparable expression levels in transduced CD34<sup>+</sup> cells (<xref rid="SD1" ref-type="supplementary-material">Supplementary Fig. 11c</xref>), mNHR2 significantly impaired the ability of AML1-ETO to maintain CD34<sup>+</sup> cells (<xref rid="F4" ref-type="fig">Fig. 4a</xref>). We also measured the frequencies of functional HSPCs using cobblestone area-forming cell (CAFC) and long-term culture-initiating cell (LTC-IC) assays. Notably, mNHR2 significantly reduced the CAFC and LTC-IC colonies in both assays, whereas mNHR1 showed relatively mild effects and no clear synergy between mNHR1 and mNHR2 was evident (<xref rid="F4" ref-type="fig">Fig. 4b, c</xref>). These results suggest that the NHR2-N2B interaction, rather than simply acting additively with the NHR1-AD1 interaction to increase binding affinity, may act as a conformational switch within AETFC (<xref rid="SD1" ref-type="supplementary-material">Supplementary Fig. 1a</xref>) and thus contribute to AML1-ETOâenhanced HSPC self-renewal. In contrast, these mutations showed no effect on AML1-ETO activities in differentiation inhibition (<xref rid="SD1" ref-type="supplementary-material">Supplementary Fig. 12</xref>) and cell growth arrest (data not shown). To exclude the possibility that mNHR2 may affect other interactions rather than the E protein-interaction, we designed (based on the structure) another NHR2 mutation (mNHR2S) that effected a similar loss of E protein-binding but differed completely in sequence from mNHR2. Nevertheless, mNHR2 and mNHR2S showed similar effects in HSPC self-renewal and differentiation (<xref rid="SD1" ref-type="supplementary-material">Supplementary Fig. 13</xref>), strongly suggesting that these effects were specifically caused by disruption of the NHR2-N2B interaction.</p>
    <p id="P9">To determine whether these interactions are also required for leukaemogenesis <italic>in vivo</italic>, we used the mouse leukaemic model<sup><xref rid="R24" ref-type="bibr">24</xref></sup> involving transplantation of mouse HSPCs transduced with WT and mutated AE9a. In this assay, mice carrying AE9a-mNHR2 showed a significant delay in leukaemogenesis compared with AE9a mice. First, AE9a-mNHR2 mice showed a significantly lower white blood cell (WBC) count than AE9a mice (<xref rid="F4" ref-type="fig">Fig. 4d</xref>), consistent with peripheral blood morphology (<xref rid="SD1" ref-type="supplementary-material">Supplementary Fig. 14a</xref>). Second, mNHR2 mice had a lower percentage of c-Kit<sup>+</sup>/Mac-1<sup>â</sup>/GFP<sup>+</sup> leukaemic blast cells in their peripheral blood (<xref rid="SD1" ref-type="supplementary-material">Supplementary Fig. 14b, c</xref>). Third, undifferentiated leukaemic cells were enriched in AE9a mice but not in mNHR2 mice (<xref rid="F4" ref-type="fig">Fig. 4e</xref>). Finally, mNHR2 mice survived significantly longer than AE9a mice (<xref rid="F4" ref-type="fig">Fig. 4f</xref>). The mNHR1 mutation again showed relatively mild effects in suppressing leukaemogenesis in mice. Taken together, both human HSPC and mouse transplantation assays clearly showed that the NHR2-N2B interaction is required for AML1-ETOâmediated leukaemogenesis. Given that the extremely high stability of the NHR2 oligomer makes its therapeutic targeting very challenging<sup><xref rid="R4" ref-type="bibr">4</xref></sup>, the NHR2-N2B interaction potentially offers a new target.</p>
    <p id="P10">In contrast to previously reported dynamic interactions of various proteins with AML1-ETO under overexpression conditions, this study provides a direct and unbiased analysis of natural AML1-ETO in leukaemic cells and identification of an endogenous stable complex (AETFC). The multiple components in AETFC offer opportunities for recruitment of AML1-ETO to a variety of target genes and for regulation of gene expression through context-dependent functional interactions with diverse transcriptional coactivators and corepressors (<xref rid="SD1" ref-type="supplementary-material">Supplementary Figs. 1 and 15</xref>; further discussion in <xref rid="SD1" ref-type="supplementary-material">Supplementary Information</xref>). In leukaemic cells, most, if not all, AML1-ETO likely resides in and functions through AETFC since (i) knockdown of other AETFC components destabilizes AML1-ETO, (ii) many AML1-ETOâregulated genes are likewise co-occupied and co-regulated by AETFC components, and (iii) knockdowns of AETFC components significantly impair leukaemogenesis. Consistent with the observation that HEB and E2A play essential roles in AETFC assembly/stabilization and in leukaemogenesis, the direct AML1-ETOâE protein interaction is shown to be required for leukaemogenesis. Among the two defined AML1-ETOâE protein interaction sites, and surprisingly, the herein-identified and structurally characterized NHR2-N2B interaction, which requires oligomerization of NHR2, is necessary and sufficient for AML1-ETOâmediated leukaemogenesis (further discussed in <xref rid="SD1" ref-type="supplementary-material">Supplementary Information</xref>). Oligomerization of transcription factors has been known as an important regulatory mechanism for modulating their DNA-binding specificity and affinity; and choice of different oligomerizing partners also contributes to selective recruitment of cofactors<sup><xref rid="R28" ref-type="bibr">28</xref>,<xref rid="R29" ref-type="bibr">29</xref></sup>. Here, the unique NHR2-N2B interaction provides a novel model in which oligomeric transcription factors use their oligomerization domains to create a new protein-binding interface. Thus, this study reveals new mechanisms of action of the oligomerized AML1-ETO in leukaemogenesis and provides potential therapeutic possibilities.</p>
    <sec sec-type="methods" id="S2" specific-use="web-only">
      <title>Methods</title>
      <sec id="S3">
        <title>Protein purification and mass spectrometry</title>
        <p id="P13">Kasumi-1 cells were grown in 12 liter spinner flasks (BellCo) and the nuclear extract was prepared by our standard high salt extraction method<sup><xref rid="R31" ref-type="bibr">31</xref></sup>. The custom anti-ETO antibody (Covance) was developed against a C-terminal peptide of ETO and purified with a recombinant protein. Complex purification was performed in buffer BC300 (20 mM Tris, pH 7.3, 300 mM KCl, 0.2 mM EDTA and 20% Glycerol) plus 0.1% NP-40. Eluted proteins were separated by SDS-PAGE and visible bands on the gel were sliced separately and subjected to LC-MS/MS analysis. For immunoblot, the following antibodies were used: ETO (Santa Cruz; sc-9737), HEB (Santa Cruz; sc-357), E2A (Santa Cruz; sc-763), LDB1 (Santa Cruz; sc-11198), LYL1 (Abcam; ab30334), CBFÎ² (Pierce; PA1-317), LMO2 (Abcam; ab81988) and SCL (a gift from Dr. R. Baer).</p>
      </sec>
      <sec id="S4">
        <title>Gel filtration</title>
        <p id="P14">The antigen-eluted complex was subjected to gel filtration with a Precision Column PC 3.2/30 that was pre-packed with Superose 6 and connected to an AKTA FPLC system (GE Healthcare). A Superdex 75 column (GE Healthcare) was used to determine the oligomeric states of WT and mutant AML1-ETO NHR2.</p>
      </sec>
      <sec id="S5">
        <title>Reconstitution of protein complex</title>
        <p id="P15">The Bac-to-Bac Baculovirus Expression Systems (Invitrogen) was used to generate recombinant baculoviruses containing each AETFC component. Reconstituted protein complexes were purified from Sf9 insect cells co-infected with different baculoviruses.</p>
      </sec>
      <sec id="S6">
        <title>ChIP and ChIP-seq</title>
        <p id="P16">Antigen-purified anti-ETO antibody and antibodies against HEB (Santa Cruz; sc-357), E2A (Santa Cruz; sc-763) and LMO2 (Abcam; ab81988) were used for ChIP and ChIP-seq assays. ChIP was performed with a dual cross-linking method. ChIP-seq libraries were constructed following the Illumina protocol and sequenced on the Illumina Genome Analyzer II. Peak-calling/annotation and consensus sequence analyses were performed with ChIPseeqer<sup><xref rid="R32" ref-type="bibr">32</xref></sup>, CisFinder<sup><xref rid="R33" ref-type="bibr">33</xref></sup> and Cisgenome<sup><xref rid="R34" ref-type="bibr">34</xref></sup>.</p>
      </sec>
      <sec id="S7">
        <title>shRNA knockdown</title>
        <p id="P17">The shRNA against AML1-ETO was designed to target the fusion site. Other lentiviral shRNA sets were purchased from Open Biosystems. Virus preparation and cell infection were performed according to manufacturerâs protocol. Knockdown efficiencies were analyzed by RT-qPCR and/or immunoblot at 4 day post-infection.</p>
      </sec>
      <sec id="S8">
        <title>RNA-seq</title>
        <p id="P18">Kasumi-1 cells with knockdowns of AETFC components were harvested at 4 day post-infection and RNA was extracted with TRIzol Reagent (Invitrogen). Libraries were generated using the TruSeq RNA Sample Preparation Kit (Illumina) and sequenced with Illumina HiSeq2000. The reads were aligned with TopHat and then processed with an in-house program to calculate the RPKM value for each gene following published methods<sup><xref rid="R35" ref-type="bibr">35</xref></sup>.</p>
      </sec>
      <sec id="S9">
        <title>Cell transfection and co-immunoprecipitation</title>
        <p id="P19">293T cells were transfected using Lipofactamine 2000 (Invitrogen). Cells lysis and Co-IP were performed with T/G lysis buffer (20 mM Tris-HCl, pH 7.5, 300 mM NaCl, 50 mM NaF, 2 mM EDTA, 1% Triton X-100 and 20% Glycerol), and proteins were analyzed by immunoblot.</p>
      </sec>
      <sec id="S10">
        <title>GST pull-down</title>
        <p id="P20">GST-tagged proteins were expressed in <italic>E. coli</italic> and purified with glutathione Sepharose 4B (GE Healthcare). The <sup>35</sup>S-labelled prey proteins were synthesized with the TNT Quick Coupled Transcription/Translation System (Promega). Pull-down assays were performed with NETN buffer (20 mM Tris-HCl, pH 8.0, 100 mM NaCl, 1 mM EDTA and 0.5% NP-40), followed by SDS-PAGE and autoradiography analyses.</p>
      </sec>
      <sec id="S11">
        <title>Co-expression of N2B fragment and NHR2 domain</title>
        <p id="P21">The His-Sumo-tagged N2B(100-219) fragment of HEB and the GST-tagged NHR2(482-551) domain of AML1-ETO were co-expressed in <italic>E. coli</italic> and purified by GST- or His-pull down. By serial truncation of N2B from both ends, a short N2B(177-200) peptide was shown to retain its binding affinity for NHR2, and this N2B fragment was used for crystallization trials.</p>
      </sec>
      <sec id="S12">
        <title>Crystallization and structure determination</title>
        <p id="P22">Purified N2B(177-200) peptide and NHR2(486-548) domain were mixed at around 1:1 ratio and subjected to crystallization trials. Crystals of the complex were grown by the hanging-drop method at 20Â°C in buffer containing 0.1 mM Tris (pH 8.5) and 20% ethanol. A 2.9 Ã resolution data set of the complex was collected on beamline 24ID-E at the Advanced Photon Source, Argonne National Laboratory. The initial model was solved by molecular replacement using the free NHR2 structure as the search model. The validation of the directionality and register of the bound N2B peptide were performed with the selenomethionine labeling method following the introduction of V186M, V194M and corresponding double mutations.</p>
      </sec>
      <sec id="S13">
        <title>Fluorescence polarization-based measurements</title>
        <p id="P23">Peptides were labeled with fluorescein at the N-terminus. FP assays were carried out and analyzed using FP buffer (10 mM TEA, 20 mM NaCl, pH 7.4)<sup><xref rid="R36" ref-type="bibr">36</xref></sup>. Titration series of protein in 10Î¼l volume and containing 100 nM fluorescinated peptide in 384-well plates were read multiple times on a Plate Chameleon II plate reader (HIDEX Oy).</p>
      </sec>
      <sec id="S14">
        <title>Human HSPC self-renewal and differentiation</title>
        <p id="P24">CD34<sup>+</sup> cells were purified from human cord blood samples using the MACS CD34 Isolation Kit (Miltenyi Biotec). After expansion, cells were infected with MIGR1-derived retroviruses. GFP<sup>+</sup>/CD34<sup>+</sup> cells were sorted and grown in basic or differentiation medium and re-plated weekly. Numbers of HSPC and differentiated cells were determined by cell counting and flow cytometry. For the CAFC assays, CD34<sup>+</sup> cells were co-cultured on an MS-5 monolayer and demi-depopulated weekly. The cobblestone areas were scored at week 5. For LTC-IC assays, the cells were plated at week 6 in methylcellulose with cytokines, and the colony numbers were scored 14 days after seeding.</p>
      </sec>
      <sec id="S15">
        <title>Mouse fetal liver transplantation and leukaemogenesis assays</title>
        <p id="P25">Mouse fetal liver HSPCs were infected with MIGR1-derived retroviruses and cultured in X-VIVO medium (Lonza) with cytokines. Recipient mice were lethally irradiated and transduced fetal liver cells were transplanted into recipient mice by tail-vein injection. Leukaemia development was determined by complete blood count, flow cytometry and morphological analyses of peripheral blood and bone marrow cells. The overall survival of the mice was analyzed by Kaplan-Meier method and the statistical significance was evaluated by the logrank test. For bioluminescent imaging of leukaemia in mice<sup><xref rid="R37" ref-type="bibr">37</xref></sup>, AE9a leukaemic cells were transduced with MSCV-Luciferase PGK-hygo (Addgene). Upon injection of the substrate of luciferase, D-Luciferin, bioluminescent imaging was performed using an IVIS100 imaging system. For gene knockdown assays in the mouse model, a mouse leukaemic cell line was generated from the spleen of the mice bearing AE9a-induced leukaemia. These cells were infected with shRNA lentiviruses, selected by puromycin and injected into recipient mice to generate leukaemia.</p>
      </sec>
    </sec>
    <sec sec-type="supplementary-material" id="S16">
      <title>Supplementary Material</title>
      <supplementary-material content-type="local-data" id="SD1">
        <label>1</label>
        <media xlink:href="NIHMS479702-supplement-1.doc" mimetype="application" mime-subtype="msword" orientation="portrait" xlink:type="simple" id="d37e713" position="anchor"/>
      </supplementary-material>
    </sec>
  </body>
  <back>
    <ack id="S17">
      <p>We thank N. A. Speck and J. H. Bushweller for providing AML1-ETO m7 plasmid, and R. Baer for providing SCL plasmids and anti-SCL antibodies. This work was supported by National Institutes of Health (NIH) grants CA163086 (R.G.R.), CA129325 (R.G.R.), CA113872 (R.G.R.) and CA166835 (S.D.N.), Starr Cancer Consortium grant I5-A554 (R.G.R., D.J.P. and S.D.N.), Leukemia and Lymphoma Society (LLS) SCOR grants 7013-02 (R.G.R. and S.D.N.) and 7132-08 (R.G.R., A.M. and D.J.P.), and Rockefeller University Center for Clinical and Translational Science Pilot Project grant UL1RR024143 from NIH (X.-J.S.). X.J.S. was a Starr Cancer Consortium Visiting Fellow. L.W. was an Empire State Stem Cell Scholar and an LLS Fellow. W.Y.C. was an LLS Fellow. D.J.P. was supported by funds from Abby Rockefeller Mauze Trust and the Maloris Foundation.</p>
    </ack>
    <fn-group>
      <fn id="FN2">
        <p><xref rid="SD1" ref-type="supplementary-material">Supplementary Information</xref> is linked to the online version of the paper at <ext-link ext-link-type="uri" xlink:href="www.nature.com/nature">www.nature.com/nature</ext-link>.</p>
      </fn>
      <fn id="FN3" fn-type="con">
        <p><bold>Author Contributions</bold> X.J.S. and R.G.R. conceived the project. R.G.R. supervised the biochemical studies. S.D.N. supervised the leukaemia pathological studies. D.J.P. supervised the structural studies. A.M. supervised the genomic studies. X.J.S., Z.W., L.W., Y.J., N.K., T.D.S., W.Y.C., Z.T., T.N., O.E. and W.F. performed the experiments and analyzed the data. X.J.S. and R.G.R. wrote the paper.</p>
      </fn>
      <fn id="FN4">
        <p>ChIP-seq and RNA-seq data have been deposited in GEO under accession number GSE43834. Crystal structure of the NHR2-N2B complex has been deposited in PDB under accession code 4JOL.</p>
      </fn>
      <fn id="FN5">
        <p>Reprints and permissions information is available at <ext-link ext-link-type="uri" xlink:href="www.nature.com/reprints">www.nature.com/reprints</ext-link>.</p>
      </fn>
      <fn id="FN6" fn-type="conflict">
        <p>The authors declare no competing financial interests.</p>
      </fn>
    </fn-group>
    <ref-list>
      <ref id="R1">
        <label>1</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Look</surname>
              <given-names>AT</given-names>
            </name>
          </person-group>
          <article-title>Oncogenic transcription factors in the human acute leukemias</article-title>
          <source>Science</source>
          <volume>278</volume>
          <fpage>1059</fpage>
          <lpage>1064</lpage>
          <year>1997</year>
          <pub-id pub-id-type="pmid">9353180</pub-id>
        </element-citation>
      </ref>
      <ref id="R2">
        <label>2</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Peterson</surname>
              <given-names>LF</given-names>
            </name>
            <name>
              <surname>Zhang</surname>
              <given-names>DE</given-names>
            </name>
          </person-group>
          <article-title>The 8;21 translocation in leukemogenesis</article-title>
          <source>Oncogene</source>
          <volume>23</volume>
          <fpage>4255</fpage>
          <lpage>4262</lpage>
          <year>2004</year>
          <pub-id pub-id-type="pmid">15156181</pub-id>
        </element-citation>
      </ref>
      <ref id="R3">
        <label>3</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Minucci</surname>
              <given-names>S</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Oligomerization of RAR and AML1 transcription factors as a novel mechanism of oncogenic activation</article-title>
          <source>Mol Cell</source>
          <volume>5</volume>
          <fpage>811</fpage>
          <lpage>820</lpage>
          <year>2000</year>
          <pub-id pub-id-type="pmid">10882117</pub-id>
        </element-citation>
      </ref>
      <ref id="R4">
        <label>4</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Liu</surname>
              <given-names>Y</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>The tetramer structure of the Nervy homology two domain, NHR2, is critical for AML1/ETOâs activity</article-title>
          <source>Cancer Cell</source>
          <volume>9</volume>
          <fpage>249</fpage>
          <lpage>260</lpage>
          <year>2006</year>
          <pub-id pub-id-type="pmid">16616331</pub-id>
        </element-citation>
      </ref>
      <ref id="R5">
        <label>5</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kwok</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Zeisig</surname>
              <given-names>BB</given-names>
            </name>
            <name>
              <surname>Qiu</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Dong</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>So</surname>
              <given-names>CW</given-names>
            </name>
          </person-group>
          <article-title>Transforming activity of AML1-ETO is independent of CBFbeta and ETO interaction but requires formation of homo-oligomeric complexes</article-title>
          <source>Proc Natl Acad Sci U S A</source>
          <volume>106</volume>
          <fpage>2853</fpage>
          <lpage>2858</lpage>
          <year>2009</year>
          <pub-id pub-id-type="pmid">19202074</pub-id>
        </element-citation>
      </ref>
      <ref id="R6">
        <label>6</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Yan</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Ahn</surname>
              <given-names>EY</given-names>
            </name>
            <name>
              <surname>Hiebert</surname>
              <given-names>SW</given-names>
            </name>
            <name>
              <surname>Zhang</surname>
              <given-names>DE</given-names>
            </name>
          </person-group>
          <article-title>RUNX1/AML1 DNA-binding domain and ETO/MTG8 NHR2-dimerization domain are critical to AML1-ETO9a leukemogenesis</article-title>
          <source>Blood</source>
          <volume>113</volume>
          <fpage>883</fpage>
          <lpage>886</lpage>
          <year>2009</year>
          <pub-id pub-id-type="pmid">19036704</pub-id>
        </element-citation>
      </ref>
      <ref id="R7">
        <label>7</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Okumura</surname>
              <given-names>AJ</given-names>
            </name>
            <name>
              <surname>Peterson</surname>
              <given-names>LF</given-names>
            </name>
            <name>
              <surname>Okumura</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Boyapati</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Zhang</surname>
              <given-names>DE</given-names>
            </name>
          </person-group>
          <article-title>t(8;21)(q22; q22) Fusion proteins preferentially bind to duplicated AML1/RUNX1 DNA-binding sequences to differentially regulate gene expression</article-title>
          <source>Blood</source>
          <volume>112</volume>
          <fpage>1392</fpage>
          <lpage>1401</lpage>
          <year>2008</year>
          <pub-id pub-id-type="pmid">18511808</pub-id>
        </element-citation>
      </ref>
      <ref id="R8">
        <label>8</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Gelmetti</surname>
              <given-names>V</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Aberrant recruitment of the nuclear receptor corepressor-histone deacetylase complex by the acute myeloid leukemia fusion partner ETO</article-title>
          <source>Mol Cell Biol</source>
          <volume>18</volume>
          <fpage>7185</fpage>
          <lpage>7191</lpage>
          <year>1998</year>
          <pub-id pub-id-type="pmid">9819405</pub-id>
        </element-citation>
      </ref>
      <ref id="R9">
        <label>9</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lutterbach</surname>
              <given-names>B</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>ETO, a target of t(8;21) in acute leukemia, interacts with the N-CoR and mSin3 corepressors</article-title>
          <source>Mol Cell Biol</source>
          <volume>18</volume>
          <fpage>7176</fpage>
          <lpage>7184</lpage>
          <year>1998</year>
          <pub-id pub-id-type="pmid">9819404</pub-id>
        </element-citation>
      </ref>
      <ref id="R10">
        <label>10</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Wang</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Hoshino</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Redner</surname>
              <given-names>RL</given-names>
            </name>
            <name>
              <surname>Kajigaya</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Liu</surname>
              <given-names>JM</given-names>
            </name>
          </person-group>
          <article-title>ETO, fusion partner in t(8;21) acute myeloid leukemia, represses transcription by interaction with the human N-CoR/mSin3/HDAC1 complex</article-title>
          <source>Proc Natl Acad Sci U S A</source>
          <volume>95</volume>
          <fpage>10860</fpage>
          <lpage>10865</lpage>
          <year>1998</year>
          <pub-id pub-id-type="pmid">9724795</pub-id>
        </element-citation>
      </ref>
      <ref id="R11">
        <label>11</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Westendorf</surname>
              <given-names>JJ</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>The t(8;21) fusion product, AML-1-ETO, associates with C/EBP-alpha, inhibits C/EBP-alpha-dependent transcription, and blocks granulocytic differentiation</article-title>
          <source>Mol Cell Biol</source>
          <volume>18</volume>
          <fpage>322</fpage>
          <lpage>333</lpage>
          <year>1998</year>
          <pub-id pub-id-type="pmid">9418879</pub-id>
        </element-citation>
      </ref>
      <ref id="R12">
        <label>12</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Mao</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Frank</surname>
              <given-names>RC</given-names>
            </name>
            <name>
              <surname>Zhang</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Miyazaki</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Nimer</surname>
              <given-names>SD</given-names>
            </name>
          </person-group>
          <article-title>Functional and physical interactions between AML1 proteins and an ETS protein, MEF: implications for the pathogenesis of t(8;21)-positive leukemias</article-title>
          <source>Mol Cell Biol</source>
          <volume>19</volume>
          <fpage>3635</fpage>
          <lpage>3644</lpage>
          <year>1999</year>
          <pub-id pub-id-type="pmid">10207087</pub-id>
        </element-citation>
      </ref>
      <ref id="R13">
        <label>13</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Elagib</surname>
              <given-names>KE</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>RUNX1 and GATA-1 coexpression and cooperation in megakaryocytic differentiation</article-title>
          <source>Blood</source>
          <volume>101</volume>
          <fpage>4333</fpage>
          <lpage>4341</lpage>
          <year>2003</year>
          <pub-id pub-id-type="pmid">12576332</pub-id>
        </element-citation>
      </ref>
      <ref id="R14">
        <label>14</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Zhang</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Kalkum</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Yamamura</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Chait</surname>
              <given-names>BT</given-names>
            </name>
            <name>
              <surname>Roeder</surname>
              <given-names>RG</given-names>
            </name>
          </person-group>
          <article-title>E protein silencing by the leukemogenic AML1-ETO fusion protein</article-title>
          <source>Science</source>
          <volume>305</volume>
          <fpage>1286</fpage>
          <lpage>1289</lpage>
          <year>2004</year>
          <pub-id pub-id-type="pmid">15333839</pub-id>
        </element-citation>
      </ref>
      <ref id="R15">
        <label>15</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Gardini</surname>
              <given-names>A</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>AML1/ETO oncoprotein is directed to AML1 binding regions and co-localizes with AML1 and HEB on its targets</article-title>
          <source>PLoS Genet</source>
          <volume>4</volume>
          <fpage>e1000275</fpage>
          <year>2008</year>
          <pub-id pub-id-type="pmid">19043539</pub-id>
        </element-citation>
      </ref>
      <ref id="R16">
        <label>16</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Guo</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Hu</surname>
              <given-names>Q</given-names>
            </name>
            <name>
              <surname>Yan</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Zhang</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
          <article-title>Multivalent binding of the ETO corepressor to E proteins facilitates dual repression controls targeting chromatin and the basal transcription machinery</article-title>
          <source>Mol Cell Biol</source>
          <volume>29</volume>
          <fpage>2644</fpage>
          <lpage>2657</lpage>
          <year>2009</year>
          <pub-id pub-id-type="pmid">19289505</pub-id>
        </element-citation>
      </ref>
      <ref id="R17">
        <label>17</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Martens</surname>
              <given-names>JH</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>ERG and FLI1 binding sites demarcate targets for aberrant epigenetic regulation by AML1-ETO in acute myeloid leukemia</article-title>
          <source>Blood</source>
          <volume>120</volume>
          <fpage>4038</fpage>
          <lpage>4048</lpage>
          <year>2012</year>
          <pub-id pub-id-type="pmid">22983443</pub-id>
        </element-citation>
      </ref>
      <ref id="R18">
        <label>18</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Wang</surname>
              <given-names>L</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>The leukemogenicity of AML1-ETO is dependent on site-specific lysine acetylation</article-title>
          <source>Science</source>
          <volume>333</volume>
          <fpage>765</fpage>
          <lpage>769</lpage>
          <year>2011</year>
          <pub-id pub-id-type="pmid">21764752</pub-id>
        </element-citation>
      </ref>
      <ref id="R19">
        <label>19</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Shia</surname>
              <given-names>WJ</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>PRMT1 interacts with AML1-ETO to promote its transcriptional activation and progenitor cell proliferative potential</article-title>
          <source>Blood</source>
          <volume>119</volume>
          <fpage>4953</fpage>
          <lpage>4962</lpage>
          <year>2012</year>
          <pub-id pub-id-type="pmid">22498736</pub-id>
        </element-citation>
      </ref>
      <ref id="R20">
        <label>20</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Miyoshi</surname>
              <given-names>H</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>The t(8;21) translocation in acute myeloid leukemia results in production of an AML1-MTG8 fusion transcript</article-title>
          <source>EMBO J</source>
          <volume>12</volume>
          <fpage>2715</fpage>
          <lpage>2721</lpage>
          <year>1993</year>
          <pub-id pub-id-type="pmid">8334990</pub-id>
        </element-citation>
      </ref>
      <ref id="R21">
        <label>21</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Wadman</surname>
              <given-names>IA</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>The LIM-only protein Lmo2 is a bridging molecule assembling an erythroid, DNA-binding complex which includes the TAL1, E47, GATA-1 and Ldb1/NLI proteins</article-title>
          <source>EMBO J</source>
          <volume>16</volume>
          <fpage>3145</fpage>
          <lpage>3157</lpage>
          <year>1997</year>
          <pub-id pub-id-type="pmid">9214632</pub-id>
        </element-citation>
      </ref>
      <ref id="R22">
        <label>22</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Follows</surname>
              <given-names>GA</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Epigenetic consequences of AML1-ETO action at the human c-FMS locus</article-title>
          <source>EMBO J</source>
          <volume>22</volume>
          <fpage>2798</fpage>
          <lpage>2809</lpage>
          <year>2003</year>
          <pub-id pub-id-type="pmid">12773394</pub-id>
        </element-citation>
      </ref>
      <ref id="R23">
        <label>23</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Huang</surname>
              <given-names>G</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>PU.1 is a major downstream target of AML1 (RUNX1) in adult mouse hematopoiesis</article-title>
          <source>Nat Genet</source>
          <volume>40</volume>
          <fpage>51</fpage>
          <lpage>60</lpage>
          <year>2008</year>
          <pub-id pub-id-type="pmid">17994017</pub-id>
        </element-citation>
      </ref>
      <ref id="R24">
        <label>24</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Yan</surname>
              <given-names>M</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>A previously unidentified alternatively spliced isoform of t(8;21) transcript promotes leukemogenesis</article-title>
          <source>Nat Med</source>
          <volume>12</volume>
          <fpage>945</fpage>
          <lpage>949</lpage>
          <year>2006</year>
          <pub-id pub-id-type="pmid">16892037</pub-id>
        </element-citation>
      </ref>
      <ref id="R25">
        <label>25</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Sanchez</surname>
              <given-names>M</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>An SCL 3â² enhancer targets developing endothelium together with embryonic and adult haematopoietic progenitors</article-title>
          <source>Development</source>
          <volume>126</volume>
          <fpage>3891</fpage>
          <lpage>3904</lpage>
          <year>1999</year>
          <pub-id pub-id-type="pmid">10433917</pub-id>
        </element-citation>
      </ref>
      <ref id="R26">
        <label>26</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Park</surname>
              <given-names>S</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Structure of the AML1-ETO eTAFH domain-HEB peptide complex and its contribution to AML1-ETO activity</article-title>
          <source>Blood</source>
          <volume>113</volume>
          <fpage>3558</fpage>
          <lpage>3567</lpage>
          <year>2009</year>
          <pub-id pub-id-type="pmid">19204326</pub-id>
        </element-citation>
      </ref>
      <ref id="R27">
        <label>27</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Mulloy</surname>
              <given-names>JC</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>The AML1-ETO fusion protein promotes the expansion of human hematopoietic stem cells</article-title>
          <source>Blood</source>
          <volume>99</volume>
          <fpage>15</fpage>
          <lpage>23</lpage>
          <year>2002</year>
          <pub-id pub-id-type="pmid">11756147</pub-id>
        </element-citation>
      </ref>
      <ref id="R28">
        <label>28</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Amoutzias</surname>
              <given-names>GD</given-names>
            </name>
            <name>
              <surname>Robertson</surname>
              <given-names>DL</given-names>
            </name>
            <name>
              <surname>Van de</surname>
              <given-names>PY</given-names>
            </name>
            <name>
              <surname>Oliver</surname>
              <given-names>SG</given-names>
            </name>
          </person-group>
          <article-title>Choose your partners: dimerization in eukaryotic transcription factors</article-title>
          <source>Trends Biochem Sci</source>
          <volume>33</volume>
          <fpage>220</fpage>
          <lpage>229</lpage>
          <year>2008</year>
          <pub-id pub-id-type="pmid">18406148</pub-id>
        </element-citation>
      </ref>
      <ref id="R29">
        <label>29</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Funnell</surname>
              <given-names>AP</given-names>
            </name>
            <name>
              <surname>Crossley</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>Homo- and heterodimerization in transcriptional regulation</article-title>
          <source>Adv Exp Med Biol</source>
          <volume>747</volume>
          <fpage>105</fpage>
          <lpage>121</lpage>
          <year>2012</year>
          <pub-id pub-id-type="pmid">22949114</pub-id>
        </element-citation>
      </ref>
      <ref id="R30">
        <label>30</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Heidenreich</surname>
              <given-names>O</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>AML1/MTG8 oncogene suppression by small interfering RNAs supports myeloid differentiation of t(8;21)-positive leukemic cells</article-title>
          <source>Blood</source>
          <volume>101</volume>
          <fpage>3157</fpage>
          <lpage>3163</lpage>
          <year>2003</year>
          <pub-id pub-id-type="pmid">12480707</pub-id>
        </element-citation>
      </ref>
      <ref id="R31">
        <label>31</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Dignam</surname>
              <given-names>JD</given-names>
            </name>
            <name>
              <surname>Lebovitz</surname>
              <given-names>RM</given-names>
            </name>
            <name>
              <surname>Roeder</surname>
              <given-names>RG</given-names>
            </name>
          </person-group>
          <article-title>Accurate transcription initiation by RNA polymerase II in a soluble extract from isolated mammalian nuclei</article-title>
          <source>Nucleic Acids Res</source>
          <volume>11</volume>
          <fpage>1475</fpage>
          <lpage>1489</lpage>
          <year>1983</year>
          <pub-id pub-id-type="pmid">6828386</pub-id>
        </element-citation>
      </ref>
      <ref id="R32">
        <label>32</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Giannopoulou</surname>
              <given-names>EG</given-names>
            </name>
            <name>
              <surname>Elemento</surname>
              <given-names>O</given-names>
            </name>
          </person-group>
          <article-title>An integrated ChIP-seq analysis platform with customizable workflows</article-title>
          <source>BMC Bioinformatics</source>
          <volume>12</volume>
          <fpage>277</fpage>
          <year>2011</year>
          <pub-id pub-id-type="pmid">21736739</pub-id>
        </element-citation>
      </ref>
      <ref id="R33">
        <label>33</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Sharov</surname>
              <given-names>AA</given-names>
            </name>
            <name>
              <surname>Ko</surname>
              <given-names>MS</given-names>
            </name>
          </person-group>
          <article-title>Exhaustive search for over-represented DNA sequence motifs with CisFinder</article-title>
          <source>DNA Res</source>
          <volume>16</volume>
          <fpage>261</fpage>
          <lpage>273</lpage>
          <year>2009</year>
          <pub-id pub-id-type="pmid">19740934</pub-id>
        </element-citation>
      </ref>
      <ref id="R34">
        <label>34</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ji</surname>
              <given-names>H</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>An integrated software system for analyzing ChIP-chip and ChIP-seq data</article-title>
          <source>Nat Biotechnol</source>
          <volume>26</volume>
          <fpage>1293</fpage>
          <lpage>1300</lpage>
          <year>2008</year>
          <pub-id pub-id-type="pmid">18978777</pub-id>
        </element-citation>
      </ref>
      <ref id="R35">
        <label>35</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Mortazavi</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Williams</surname>
              <given-names>BA</given-names>
            </name>
            <name>
              <surname>McCue</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Schaeffer</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Wold</surname>
              <given-names>B</given-names>
            </name>
          </person-group>
          <article-title>Mapping and quantifying mammalian transcriptomes by RNA-Seq</article-title>
          <source>Nat Methods</source>
          <volume>5</volume>
          <fpage>621</fpage>
          <lpage>628</lpage>
          <year>2008</year>
          <pub-id pub-id-type="pmid">18516045</pub-id>
        </element-citation>
      </ref>
      <ref id="R36">
        <label>36</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Jacobs</surname>
              <given-names>SA</given-names>
            </name>
            <name>
              <surname>Fischle</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Khorasanizadeh</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
          <article-title>Assays for the determination of structure and dynamics of the interaction of the chromodomain with histone peptides</article-title>
          <source>Methods Enzymol</source>
          <volume>376</volume>
          <fpage>131</fpage>
          <lpage>148</lpage>
          <year>2004</year>
          <pub-id pub-id-type="pmid">14975303</pub-id>
        </element-citation>
      </ref>
      <ref id="R37">
        <label>37</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Zuber</surname>
              <given-names>J</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Mouse models of human AML accurately predict chemotherapy response</article-title>
          <source>Genes Dev</source>
          <volume>23</volume>
          <fpage>877</fpage>
          <lpage>889</lpage>
          <year>2009</year>
          <pub-id pub-id-type="pmid">19339691</pub-id>
        </element-citation>
      </ref>
    </ref-list>
  </back>
  <floats-group>
    <fig id="F1" orientation="portrait" position="float">
      <label>Figure 1</label>
      <caption>
        <title>AML1-ETO resides in and functions through AETFC</title>
        <p><bold>a</bold>, SDS-PAGE and silver staining of AETFC isolated from Kasumi-1 nuclear extract. Asterisks, non-specific bands. <bold>b</bold>, Co-IP and immunoblot confirmation of AETFC components. Asterisk, IgG signal. <bold>c</bold>, Schematic of interactions within AETFC. Thick and thin lines denote strong and weak interactions, respectively. Double spheres denote potential homodimerization of components. <bold>d</bold>, ChIP-seq and ChIP-qPCR analyses of AETFC components on <italic>CSF1R</italic> and <italic>SPI1</italic>. <bold>e</bold>, Correlation between AE and LDB1 in regulating gene expression. <bold>f</bold>, Knockdown of AETFC components delays AE9a-induced leukaemogenesis in mice, indicated by representative bioluminescent imaging (upper) and survival curves (bottom; n = 10; ***P&lt;0.001; **P&lt;0.01).</p>
      </caption>
      <graphic xlink:href="nihms479702f1"/>
    </fig>
    <fig id="F2" orientation="portrait" position="float">
      <label>Figure 2</label>
      <caption>
        <title>Oligomerized AML1-ETO NHR2 domain mediates a specific interaction with E proteins</title>
        <p><bold>a</bold>, Alignment of NHR2 of ETO family proteins. Arrows denote residues mutated to alanine in mutants am1â10 screened herein and the m7 mutant that disrupts NHR2-oligomerization<sup><xref rid="R4" ref-type="bibr">4</xref></sup>. <bold>b</bold>, Identification of mutations that disrupt the interaction between AE and HEB-ÎAD1. <bold>c</bold>, Gel-filtration profiles of WT and mutant NHR2. WT and am1+9 were eluted as oligomers, and m7 as a monomer. <bold>d</bold>, Distinct surfaces of the NHR2 Î±-helix mediate oligomerization and the E protein interaction. <bold>e</bold>, NHR2-oligomerization is required for the NHR2-E protein interaction. Mutant-mutant AE homodimer (lanes 1, 4), mutant-WT heterodimer (lanes 2, 5) and WT-WT homodimer (lanes 3, 6) were formed in 293T cells by co-expression of WT AE and NHR2-mutated AE (âXXâ) that fails to interact with HEB-ÎAD1, and their abilities to bind to HEB-ÎAD1 were determined by co-IP.</p>
      </caption>
      <graphic xlink:href="nihms479702f2"/>
    </fig>
    <fig id="F3" orientation="portrait" position="float">
      <label>Figure 3</label>
      <caption>
        <title>Structural details of the NHR2-N2B interaction</title>
        <p><bold>a</bold>, Alignment of the N2B regions of vertebrate E proteins. Arrows denote residues mutated to alanine in mutants am1â8. <bold>b</bold>, Identification of the N2B motif by co-IP. <bold>c</bold>, Side (upper) and look-down (bottom) ribbon views of the structure of the complex between the N2B(177-200) peptide and the tetrameric-helical bundle of NHR2. The N2B peptide is shown in stick representation, and the NHR2 helices in ribbon representation. <bold>d</bold>, Positioning of the N2B peptide on the electrostatic surface of the NHR2 tetramer. <bold>e</bold>, One N2B peptide interacts with two NHR2 helices through hydrogen bonds. <bold>f</bold>, <bold>g</bold>, FP analysis of the binding between NHR2 and a shorter N2B(182-196) peptide, comparing WT and indicated mutants of NHR2 (<bold>f</bold>) and N2B (<bold>g</bold>). n=3; mean Â± s.d.</p>
      </caption>
      <graphic xlink:href="nihms479702f3"/>
    </fig>
    <fig id="F4" orientation="portrait" position="float">
      <label>Figure 4</label>
      <caption>
        <title>Role of the AML1-ETOâE protein interactions in human HSPC self-renewal and mouse leukaemogenesis</title>
        <p><bold>a,</bold> Effects of AE and derived mutants in maintenance of human CD34<sup>+</sup> cells. <bold>b</bold>, CAFC assays measuring the frequency of functional HSPCs in cells transduced with AE or derived mutants. <bold>c</bold>, LTC-IC assays measuring the frequency of functional HSPCs after long-term <italic>in vitro</italic> culture of cells transduced with AE or derived mutants. In <bold>aâc</bold>, n=3; mean Â± s.d. <bold>d</bold>, Effects of AE9a and derived mutants in mouse leukaemogenesis, as indicated by WBC count of peripheral blood at 4 months post transplantation. <bold>e</bold>, Morphological analysis of mouse bone marrow cells. <bold>f</bold>, Kaplan-Meier survival curves of the mice (n = 15).</p>
      </caption>
      <graphic xlink:href="nihms479702f4"/>
    </fig>
  </floats-group>
</article>

</metadata></record></GetRecord></OAI-PMH>